Kazia stated that in murine triple-negative breast cancer preclinical models, NDL2 reduced primary tumor volume by 49% as ...

Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.

Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression ...

Cancer immunotherapy has transformed modern oncology by harnessing the body's own immune system to combat malignant disease.

The Sydney-based oncology company revealed that NDL2 is designed to eliminate nuclear PD-L1, which Kazia identified as a previously unrecognized driver of immunotherapy resistance and metastatic ...

The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...

Cancer immunotherapy has been a game-changer, but many tumors still find ways to slip past the immune system. New research ...

A proposed model illustrating how tumor cells release PD-L1-containing small extracellular vesicles (sEVs) that suppress ...

DUBLIN--(BUSINESS WIRE)--The "PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline And Competitor Analysis From An Industry Perspective" report has been added to ResearchAndMarkets ...

PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...